| abstract |
The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as nucleic acid constructs encoding such variants, vectors and host cells comprising and expressing the nucleic acid, pharmaceutical compositions, uses and methods of treatment. The variant comprises a substitution in at least one amino acid position, selected from the group consisting of positions Lys 157, Lys 337, Asp 334, Ser 336, Val 158, Glu 296 and Met 298. |